Swedish Drug And Device To Go Head-To-Head In The GERD Space

Two Swedish companies are working on tackling GERD – one with a drug, one with a device.

reflux
• Source: Shutterstock

Cinclus Pharma and Implantica, a duo of Swedish companies, are working to create new therapies for gastroesophageal reflux disease (GERD) but are approaching the problem from opposite ends of the health care spectrum.

Implantica has developed RefluxStop, a CE-marked implant designed to transform the anatomical features associated with GERD.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Strategy

Siemens Healthineers Mitigates Headwinds With ‘Value-Add Structural Changes’

 

Siemens Healthineers anticipates €400m-€500m tariff impact by 2026 but says it will mitigate losses through structural changes and pricing. Despite a revenue decline in diagnostics due to China’s VBP, diagnostics transformation activities, including cutting product, were “successful."

GE HealthCare Halves 2025 Tariff EPS Hit As Global Supply Chain Realigns

 
• By 

For the third quarter of 2025, GE HealthCare projects year-over-year organic revenue growth in the range of 2%-3%. However, adjusted EPS is expected to decline in the high single digits year-over-year, reflecting the ongoing effect of tariff costs.

CorTec Begins First Human Trial Of Wireless Brain Implant For Stroke Rehab

 
• By 

Germany’s CorTec has implanted its wireless brain-computer interface in a stroke patient, launching a trial to test safety and whether brain stimulation during physical therapy can help restore movement where traditional rehab has failed.

Thermo Fisher Margins Feel The Weight Of Tariffs Even As China Trade Pressures Ease In Q2

 
• By 

Thermo Fisher said the year-over-year impact of tariffs and related effects represented a 5% headwind to adjusted operating income and reduced reported margins by 140 basis points in the second quarter.

More from Business

FDA’s Small Business Eligibility Process Gets Update Before New Fiscal Year

 
• By 

The US FDA has updated its guidance document on small business eligibility determinations for medical device firms. Industry observers urge companies to ask for the status early to avoid any potential hold-ups.

Thermo Fisher Margins Feel The Weight Of Tariffs Even As China Trade Pressures Ease In Q2

 
• By 

Thermo Fisher said the year-over-year impact of tariffs and related effects represented a 5% headwind to adjusted operating income and reduced reported margins by 140 basis points in the second quarter.

NIH-Backed Scanner Opens New Frontier For Understanding The Human Brain

 

A new MRI scanner developed by a team of scientists working with the National Institutes of Health marks a milestone in understanding the complexities of the human brain. Andrea Beckel-Mitchener with the NIH Brain Initiative discusses the significance of this potentially game-changing device.